GRN-300 is under clinical development by Greenfire Bio and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect GRN-300’s likelihood of approval (LoA) and phase transition for Ovarian Cancer took place on 28 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GRN-300 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
GRN-300 is under development for the treatment of recurrent ovarian cancer, endometrial cancer, primary peritoneal cancer, fallopian tube cancer, triple-negative breast cancer, prostate cancer, acute myeloid leukemia (AML), diffuse large B-cell lymphoma and lung cancer. It is administered through oral route. It acts by targeting serine/threonine-protein kinase (SIK2) and serine/threonine-protein kinase (SIK3). The drug candidate is developed based on fragment-field drug design (FFDD) technology platform.
Greenfire Bio overview
Greenfire Bio (Greenfire) is a life science company that builds a diversified product pipeline by developing early-stage assets. The company acquires, licenses, partners and invests in differentiated pre-clinical oearly clinical stage medical products to bridge the translational medicine gap and accelerate development. Its lead product candidate GRN-300, an orally bioavailable small molecule dual inhibitor of salt inducible kinases 2 and 3 (SIK2, SIK3) for the treatment ovarian cancer. Greenfire is also evaluating drugs targeting triple-negative breast cancer (TNBC), prostate, diffuse large B-cell lymphoma (DLBCL), melanoma and AML cancers. Greenfire is headquartered in Austin, Texas, the US.
Quick View GRN-300 LOA Data
|Highest Development Stage|